Analysis of the profitability of adult vaccination in 13 private provider practices in the United States.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
30 09 2019
Historique:
received: 04 03 2019
revised: 21 08 2019
accepted: 22 08 2019
pubmed: 10 9 2019
medline: 22 9 2020
entrez: 10 9 2019
Statut: ppublish

Résumé

Vaccination coverage among adults remains low in the United States. Understanding the barriers to provision of adult vaccination is an important step to increasing vaccination coverage and improving public health. To better understand financial factors that may affect practice decisions about adult vaccination, this study sought to understand how costs compared with payments for adult vaccinations in a sample of U.S. physician practices. We recruited a convenience sample of 19 practices in nine states in 2017. We conducted a time-motion study to assess the time costs of vaccination activities and conducted a survey of practice managers to assess materials, management, and dose costs and payments for vaccination. We received complete cost and payment data from 13 of the 19 practices. We calculated annual income from vaccination services by comparing estimated costs with payments received for vaccine doses and vaccine administration. Median annual total income from vaccination services was $90,343 at family medicine practices (range: $3968-$249,628), $28,267 at internal medicine practices (-$32,659-$141,034) and $2886 at obstetrics and gynecology practices (-$73,451-$23,820). Adult vaccination was profitable at the median of our sample, but there is wide variation in profitability due to differences in costs and payment rates across practices. This study provides evidence on the financial viability of adult vaccination and supports actions for improving financial viability. These results can help inform practices' decisions whether to provide adult vaccines and contribute to keeping adults up-to-date with the recommended vaccination schedule.

Identifiants

pubmed: 31495594
pii: S0264-410X(19)31130-2
doi: 10.1016/j.vaccine.2019.08.056
pmc: PMC6778689
mid: NIHMS1049380
pii:
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

6180-6185

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Ann Intern Med. 2019 Feb 5;170(3):182-92
pubmed: 30716757
Vaccine. 2019 Feb 4;37(6):792-797
pubmed: 30639460
Ann Intern Med. 2014 Feb 4;160(3):161
pubmed: 24658693
MMWR Morb Mortal Wkly Rep. 2014 Apr 25;63(16):352-5
pubmed: 24759657
Am J Prev Med. 2016 Dec;51(6):1079-1083
pubmed: 27236479
Obstet Gynecol Surv. 2009 Dec;64(12):823-9
pubmed: 19939296
MMWR Surveill Summ. 2017 May 05;66(11):1-28
pubmed: 28472027
Public Health Rep. 2012 Jan-Feb;127 Suppl 1:1-42
pubmed: 22210957
Ann Intern Med. 2018 Feb 6;168(3):210-220
pubmed: 29404596
Vaccine. 2016 Sep 30;34(42):5060-5065
pubmed: 27614782
Vaccine. 2017 Jan 23;35(4):647-654
pubmed: 28024954
Health Aff (Millwood). 2016 Nov 1;35(11):2124-2132
pubmed: 27733424
Vaccine. 2018 Feb 14;36(8):1093-1100
pubmed: 29366706

Auteurs

Benjamin Yarnoff (B)

RTI International, Research Triangle Park, NC, United States. Electronic address: byarnoff@rti.org.

Olga Khavjou (O)

RTI International, Research Triangle Park, NC, United States.

Grant King (G)

RTI International, Research Triangle Park, NC, United States.

Laurel Bates (L)

RTI International, Research Triangle Park, NC, United States.

Fangjun Zhou (F)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Andrew J Leidner (AJ)

Berry Technology Solutions, Atlanta, GA, United States.

Angela K Shen (AK)

National Vaccine Program Office, Office of the Assistant Secretary for Health, US Department of Health and Human Services, Washington, DC, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH